Tape/Workbook Helps Breast Cancer Patients Decide on Therapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

SAN ANTONIO--A new decision aid, developed by a group of Canadian researchers, uses an audiotape and a workbook to help women with early-stage breast cancer decide between mas-tectomy and breast-conserving surgery with radiation therapy.

SAN ANTONIO--A new decision aid, developed by a group of Canadian researchers,uses an audiotape and a workbook to help women with early-stage breastcancer decide between mas-tectomy and breast-conserving surgery with radiationtherapy.

"Since the long-term survival of each option is equivalent, whethera woman chooses one or the other is very much based on her personal preference,"Carol A. Sawka, MD, of the Toronto-Sunnybrook Regional Cancer Center, saidat a poster session of the San Antonio Breast Cancer Symposium.

The researchers first developed a set of critical content items forthe information aid, and then consulted several focus groups for feedbackon the usefulness of the information.

"The women all wanted an information aid that would not replacetheir time with the surgeon but, rather, augment it. They wanted somethingthey could use at home later and go over many times," Dr. Sawka said.

The investigators learned from the focus groups that an audiotape wouldbe helpful so that patients could hear a woman's voice, "a sympatheticvoice," Dr. Sawka emphasized. They then adapted the audiotape workbookformat developed by Annette O'Connor in Ottawa. "The tape runs 26minutes, and women go through it with the workbook page by page,"she said.

The program differs from a simple educational pamphlet because it providesexplicit probabilities about, for example, possible reactions to radiationtherapy, with pictures showing what these reactions look like. It coversthe differences in surgical approach, need for radiation treatment, short-and long-term side effects of radiation, risks of recurrence, and follow-upschedule.

Values Clarification

At the end of the program, the workbook takes the patient through avalues clarification exercise in which the woman considers the personalimportance to her of the possible risks and benefits for each treatment."It is basically a scale that allows women to weigh the pros and consof each approach, to help them understand where they fit," Dr. Sawkasaid.

Results of a pilot study of 18 women showed that, by and large, womenliked the program, found it very useful, and felt that it helped to clarifyinformation about treatment without raising extra questions. They alsosaid that the decision aid did not increase their anxiety about their breastcancer diagnosis.

Based on the pilot study, the researchers have created a new versionof the decision aid and are now conducting a randomized trial of 200 women,in which surgeons provide patients with either the audiotape/workbook ora standard pamphlet that has the same information but without explicitprobabilities, photographs, or the values clarification exercise. Outcomeswill be comprehension, decisional conflict, anxiety, and post- decisionalregret.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.